mitomycin has been researched along with Hematologic Diseases in 25 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 9.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "We examined red cell fragmentation syndrome (RCFS) induced by mitomycin C (MMC) (13 patients), by thrombotic thrombocytopenic purpura (TTP) (17 patients), and by disseminated intravascular coagulation (DIC) (15 patients)." | 7.69 | Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. ( Deguchi, K; Minami, N; Miyanishi, E; Nagaya, S; Oka, K; Tamaki, S; Tanigawa, M; Tsuzi, K; Wada, H; Wakita, Y, 1995) |
| "Fanconi anemia (FA) is a clinically and genetically heterogenous disease that is usually diagnosed on the basis of chromosomal instability reflecting the hypersensitivity towards the DNA cross-linking agents diepoxybutane (DEB) and/or mitomycin C." | 7.69 | Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. ( Friedl, R; Hentze, S; Hoehn, H; Schindler, D; Schroeder-Kurth, T; Seyschab, H; Sun, Y, 1995) |
| "Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen." | 5.27 | Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Perez, DJ; Powles, TJ, 1984) |
| "We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)." | 5.09 | Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001) |
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 5.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "The FAM combination with the simultaneous administration of 5-fluorouracil, doxorubicin, and mitomycin C is considered standard chemotherapy for gastric adenocarcinoma." | 5.05 | Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. ( Athens, J; Chen, TT; Costanzi, JJ; Haas, C; Heilbrun, LK; McDonald, B; Oishi, N; Panettiere, FJ; Talley, RW, 1984) |
| "We examined red cell fragmentation syndrome (RCFS) induced by mitomycin C (MMC) (13 patients), by thrombotic thrombocytopenic purpura (TTP) (17 patients), and by disseminated intravascular coagulation (DIC) (15 patients)." | 3.69 | Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. ( Deguchi, K; Minami, N; Miyanishi, E; Nagaya, S; Oka, K; Tamaki, S; Tanigawa, M; Tsuzi, K; Wada, H; Wakita, Y, 1995) |
| "Fanconi anemia (FA) is a clinically and genetically heterogenous disease that is usually diagnosed on the basis of chromosomal instability reflecting the hypersensitivity towards the DNA cross-linking agents diepoxybutane (DEB) and/or mitomycin C." | 3.69 | Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. ( Friedl, R; Hentze, S; Hoehn, H; Schindler, D; Schroeder-Kurth, T; Seyschab, H; Sun, Y, 1995) |
| "Mitomycin-C/cisplatin were used to treat 33 evaluable patients aged 29-67 years (median: 50 years)." | 2.70 | Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. ( Anastasopoulou, A; Einhorn, N; Lacave, AJ; Mangioni, C; Neijt, JP; Pecorelli, S; Rotmensz, N; van der Burg, ME; van Oosterom, AT; Veenhof, CH; Vermorken, JB; Wagenaar, HC; Zola, P, 2001) |
| "Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment." | 2.69 | Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. ( Astoul, P; Boutin, C; Kasseyet, S, 1999) |
| "One patient with metastatic colon cancer had a partial response of liver metastases." | 2.69 | Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors. ( de Boer-Dennert, M; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; Verweij, J; Winograd, B, 1999) |
| "Acute hematotoxicity (G3, 4, 5 according to Common Terminology Criteria for Adverse Events - CTCAE) was significantly associated with the concomitant chemoradiotherapy (P = 0." | 1.56 | Haematotoxicity in IMRT/VMAT curatively treated anal cancer. ( Drbohlavová, T; Jirkovská, M; Lohynská, R; Malinová, B; Mazaná, E; Nýdlová, A; Stankušová, H; Veselský, T, 2020) |
| "Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity." | 1.38 | Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. ( Blaszkowsky, LS; Coen, JJ; Hartshorn, K; Hong, TS; Kachnic, LA; Kwak, EL; Ryan, DP; Tsai, HK; Willins, JD, 2012) |
| "The prognosis of locally advanced cervix cancers is poor with metastatic and local recurrence risks." | 1.31 | [Chemoradiotherapy in locally advanced cancers of the uterine neck. Retrospective study of 92 patients treated at the Institute Curie between 1986 and 1998]]. ( Beuzeboc, P; Chauveinc, L; Clough, KB; Cosset, JM; de la Rochefordière, A; Guyonnet, M; Mouret-Fourme, E; Nguyen, D, 2002) |
| "Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen." | 1.27 | Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Perez, DJ; Powles, TJ, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (24.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lohynská, R | 1 |
| Nýdlová, A | 1 |
| Drbohlavová, T | 1 |
| Mazaná, E | 1 |
| Jirkovská, M | 1 |
| Veselský, T | 1 |
| Malinová, B | 1 |
| Stankušová, H | 1 |
| Ahlgren, J | 1 |
| Patel, N | 1 |
| Simmens, S | 1 |
| Akin, E | 1 |
| Bishop, C | 1 |
| Kirkel, D | 1 |
| Siegel, P | 1 |
| Schuck, S | 1 |
| Guebre-Xabiher, H | 1 |
| Siegel, R | 1 |
| Yeung, R | 1 |
| McConnell, Y | 1 |
| Warkentin, H | 1 |
| Graham, D | 1 |
| Warkentin, B | 1 |
| Joseph, K | 1 |
| Doll, CM | 1 |
| Franco, P | 2 |
| Ragona, R | 2 |
| Arcadipane, F | 2 |
| Mistrangelo, M | 2 |
| Cassoni, P | 2 |
| Rondi, N | 2 |
| Morino, M | 2 |
| Racca, P | 2 |
| Ricardi, U | 2 |
| Kachnic, LA | 1 |
| Tsai, HK | 1 |
| Coen, JJ | 1 |
| Blaszkowsky, LS | 1 |
| Hartshorn, K | 1 |
| Kwak, EL | 1 |
| Willins, JD | 1 |
| Ryan, DP | 1 |
| Hong, TS | 1 |
| Nguyen, D | 1 |
| de la Rochefordière, A | 1 |
| Chauveinc, L | 1 |
| Cosset, JM | 1 |
| Clough, KB | 1 |
| Beuzeboc, P | 1 |
| Mouret-Fourme, E | 1 |
| Guyonnet, M | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Zschaber, R | 1 |
| Kehr, A | 1 |
| Schulz, J | 1 |
| Hossfeld, DK | 1 |
| Al-Batran, SE | 1 |
| Kerber, A | 1 |
| Atmaca, A | 1 |
| Dechow, C | 1 |
| Reitsamer, E | 1 |
| Schmidt, S | 1 |
| Kolassa, Y | 1 |
| Neumann, A | 1 |
| Weidmann, E | 1 |
| Hartmann, JT | 1 |
| Jäger, E | 1 |
| Perez, DJ | 1 |
| Powles, TJ | 2 |
| Gazet, JC | 1 |
| Ford, HT | 1 |
| Coombes, RC | 1 |
| Bukowski, RM | 1 |
| Balcerzak, SP | 1 |
| O'Bryan, RM | 1 |
| Bonnet, JD | 1 |
| Chen, TT | 2 |
| Panettiere, FJ | 1 |
| Haas, C | 1 |
| McDonald, B | 1 |
| Costanzi, JJ | 1 |
| Talley, RW | 1 |
| Athens, J | 1 |
| Oishi, N | 1 |
| Heilbrun, LK | 1 |
| Luikart, SD | 1 |
| Witman, GB | 1 |
| Portlock, CS | 1 |
| Nagaya, S | 1 |
| Wada, H | 1 |
| Oka, K | 1 |
| Tanigawa, M | 1 |
| Tamaki, S | 1 |
| Tsuzi, K | 1 |
| Miyanishi, E | 1 |
| Wakita, Y | 1 |
| Minami, N | 1 |
| Deguchi, K | 1 |
| Seyschab, H | 1 |
| Friedl, R | 1 |
| Sun, Y | 1 |
| Schindler, D | 1 |
| Hoehn, H | 1 |
| Hentze, S | 1 |
| Schroeder-Kurth, T | 1 |
| Kusenda, Z | 1 |
| Kerger, J | 1 |
| Awada, A | 1 |
| Geurs, F | 1 |
| Van Vreckem, A | 1 |
| Habboubi, N | 1 |
| Piccart, MJ | 1 |
| Gregory, RK | 1 |
| Chang, JC | 1 |
| Ashley, S | 1 |
| Kasseyet, S | 1 |
| Astoul, P | 1 |
| Boutin, C | 1 |
| Planting, AS | 1 |
| Schellens, JH | 1 |
| van der Burg, ME | 2 |
| de Boer-Dennert, M | 1 |
| Winograd, B | 1 |
| Stoter, G | 1 |
| Verweij, J | 1 |
| Dobrowsky, W | 1 |
| Naudé, J | 1 |
| Chen, JS | 1 |
| Lin, YC | 1 |
| Jan, YY | 1 |
| Liau, CT | 1 |
| Wagenaar, HC | 1 |
| Pecorelli, S | 1 |
| Mangioni, C | 1 |
| Rotmensz, N | 1 |
| Anastasopoulou, A | 1 |
| Zola, P | 1 |
| Veenhof, CH | 1 |
| Lacave, AJ | 1 |
| Neijt, JP | 1 |
| van Oosterom, AT | 1 |
| Einhorn, N | 1 |
| Vermorken, JB | 1 |
| Atagi, S | 1 |
| Kawahara, M | 1 |
| Hosoe, S | 1 |
| Ogawara, M | 1 |
| Kawaguchi, T | 1 |
| Okishio, K | 1 |
| Naka, N | 1 |
| Sunami, T | 1 |
| Mitsuoka, S | 1 |
| Akira, M | 1 |
| Cullinan, SA | 1 |
| Moertel, CG | 1 |
| Fleming, TR | 1 |
| Rubin, JR | 1 |
| Krook, JE | 1 |
| Everson, LK | 1 |
| Windschitl, HE | 1 |
| Twito, DI | 1 |
| Marschke, RF | 1 |
| Foley, JF | 1 |
| Wernz, JC | 1 |
| Kao, AK | 1 |
| Muggia, FM | 1 |
| Asbury, RF | 1 |
13 trials available for mitomycin and Hematologic Diseases
| Article | Year |
|---|---|
Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycyti | 2004 |
Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose- | 2007 |
Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Therapy, | 1983 |
Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1984 |
Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Topics: Adult; Aged; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas | 1997 |
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 1997 |
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality | 1999 |
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug; | 1999 |
Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Chi-Square Distribution; Combine | 2000 |
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2001 |
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2001 |
A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 2002 |
A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Costs and | 1985 |
12 other studies available for mitomycin and Hematologic Diseases
| Article | Year |
|---|---|
Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2020 |
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2015 |
Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2017 |
Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; Chemoradio | 2016 |
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squam | 2012 |
[Chemoradiotherapy in locally advanced cancers of the uterine neck. Retrospective study of 92 patients treated at the Institute Curie between 1986 and 1998]].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2002 |
Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1984 |
Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Res | 1984 |
Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Cytokines; Disseminated Intravascular | 1995 |
Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia.
Topics: Cells, Cultured; Chromosome Aberrations; Chromosomes; Cross-Linking Reagents; Drug Resistance; Epoxy | 1995 |
Mitomycin and methotrexate: negative experience in untreated colorectal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Hem | 1985 |